Published in Int Urogynecol J Pelvic Floor Dysfunct on August 07, 2008
The minimum important difference for the Pelvic Organ Prolapse-Urinary Incontinence Sexual Function Questionnaire. Int Urogynecol J (2014) 0.90
A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder. BMC Med Res Methodol (2009) 0.84
Efficacy and tolerability of fesoterodine in women with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct (2009) 0.81
Shortcomings/strengths of specific sexual function questionnaires currently used in urogynecology: a literature review. Int Urogynecol J Pelvic Floor Dysfunct (2009) 0.79
Effect of improvement in lower urinary tract symptoms on sexual function in men: tamsulosin monotherapy vs. combination therapy of tamsulosin and solifenacin. Korean J Urol (2014) 0.79
Update on tolterodine extended-release for treatment of overactive bladder. Open Access J Urol (2010) 0.78
Continued symptom improvement in sexually active women with overactive bladder and urgency urinary incontinence treated with tolterodine ER for 6 months. Int Urogynecol J Pelvic Floor Dysfunct (2009) 0.78
Persistence and compliance with medication management in the treatment of overactive bladder. Investig Clin Urol (2016) 0.77
Pathophysiology of sexual dysfunction as related to pelvic floor disorders. Int Urogynecol J Pelvic Floor Dysfunct (2009) 0.77
Management of urinary incontinence. P T (2012) 0.76
The Relationship Between Anxiety and Overactive Bladder or Urinary Incontinence Symptoms in the Clinical Population. Urology (2016) 0.75
Overactive bladder - 18 years - Part II. Int Braz J Urol (2016) 0.75
The hospital anxiety and depression scale. Acta Psychiatr Scand (1983) 121.58
Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol (2006) 7.13
A new instrument to measure sexual function in women with urinary incontinence or pelvic organ prolapse. Am J Obstet Gynecol (2001) 2.93
Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology (2001) 1.92
Prevalence and correlation of urinary incontinence and overactive bladder in Taiwanese women. Neurourol Urodyn (2003) 1.85
The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol (2006) 1.77
Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology (2001) 1.53
Sexual function among women with urinary incontinence and pelvic organ prolapse. Am J Obstet Gynecol (2004) 1.53
The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health (2004) 1.52
Urinary incontinence and depression. J Urol (1999) 1.51
Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int (2006) 1.50
Development and validation of patient-reported outcomes measures for overactive bladder: a review of concepts. Urology (2006) 1.35
Prevalence and correlates of sexual activity and function in women: results from the Boston Area Community Health (BACH) Survey. Arch Sex Behav (2008) 1.34
Sexual dysfunction is common in women with lower urinary tract symptoms and urinary incontinence: results of a cross-sectional study. Eur Urol (2004) 1.32
The effect of urinary incontinence and overactive bladder symptoms on quality of life in young women. BJU Int (2002) 1.19
Development of a questionnaire on sexual quality of life in women. J Sex Marital Ther (2005) 0.98
Severe depression determines quality of life in urinary incontinent women. Neurourol Urodyn (2003) 0.96
Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care (2002) 0.90
Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology (2004) 0.87
Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder. Eur Urol (2006) 0.86
Overactive bladder in women: symptom impact and treatment expectations. Curr Med Res Opin (2005) 0.84
The relationship between clinical parameters and health-related quality of life as measured by the 15D in incontinent women before and after treatment. Acta Obstet Gynecol Scand (2004) 0.83
The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. Am J Obstet Gynecol (2006) 0.83
A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT). Clin Ther (2002) 0.81
Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World J Urol (2004) 0.81
Overactive bladder and women's sexual health: what is the impact? J Sex Med (2007) 0.80
Reviewing the ICS 2002 terminology report: The ongoing debate. Neurourol Urodyn (2006) 0.78
The effect of overactive bladder syndrome on the sexual quality of life in Korean young and middle aged women. Int J Impot Res (2005) 0.78
Premenopausal women with sexual dysfunction: the need for a bladder function history. J Sex Med (2007) 0.77
Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA (2006) 4.15
Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. Eur Urol (2008) 2.84
Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol (2008) 2.58
Patient-reported reasons for discontinuing overactive bladder medication. BJU Int (2009) 1.94
Prevalence and effect on health-related quality of life of overactive bladder in older americans: results from the epidemiology of lower urinary tract symptoms study. J Am Geriatr Soc (2011) 1.89
The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL. Neurourol Urodyn (2012) 1.82
Age related pathogenesis of nocturia in patients with overactive bladder. J Urol (2007) 1.57
Transabdominal ultrasonography of detrusor wall thickness in women with overactive bladder. BJU Int (2009) 1.46
Evaluation of physical fitness in an ambulatory setting. Am J Obstet Gynecol (2007) 1.45
Fesoterodine dose response in subjects with overactive bladder syndrome. Urology (2008) 1.41
Postmenopausal uterine bleeding profiles with two forms of continuous combined hormone replacement therapy. Menopause (2002) 1.41
Development and validation of patient-reported outcomes measures for overactive bladder: a review of concepts. Urology (2006) 1.35
Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Manag Care (2005) 1.34
Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms. BJU Int (2011) 1.31
Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol (2007) 1.27
Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J Urol (2008) 1.16
Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology (2006) 1.12
The validation of patient-rated global assessments of treatment benefit, satisfaction, and willingness to continue--the BSW. Value Health (2005) 1.11
Age and the prevalence of bleeding disorders in women with menorrhagia. Obstet Gynecol (2005) 1.10
Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril (2009) 1.10
Impact of physician gender on sexual history taking in a multispecialty practice. J Sex Med (2006) 1.10
Dynamic progression of overactive bladder and urinary incontinence symptoms: a systematic review. Eur Urol (2010) 1.04
Predictors of discontinuing overactive bladder medications. BJU Int (2009) 1.04
Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int (2010) 1.01
Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study). J Clin Hypertens (Greenwich) (2005) 1.00
The responsiveness of the OAB-q among OAB patient subgroups. Neurourol Urodyn (2007) 1.00
Development of a screening tool for identifying women with menorrhagia for hemostatic evaluation. Am J Obstet Gynecol (2008) 0.97
Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology (2006) 0.94
Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU Int (2010) 0.94
Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU Int (2006) 0.92
Bother related to bladder control and health care seeking behavior in adults in the United States. J Urol (2009) 0.92
Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate. J Womens Health (Larchmt) (2009) 0.91
Hormonal manipulation in women with chronic, cyclic irritable bladder symptoms and pelvic pain. Am J Obstet Gynecol (2002) 0.90
Impact of overactive bladder on work productivity. Urology (2012) 0.89
Sildenafil citrate for female sexual arousal disorder: a future possibility? Nat Rev Urol (2009) 0.89
Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. BJU Int (2006) 0.87
Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity. BJU Int (2009) 0.87
Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder. Urology (2009) 0.87
Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder. Eur Urol (2006) 0.86
Challenges for managing overactive bladder and guidance for patient support. Am J Manag Care (2009) 0.84
Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology (2008) 0.84
Goal attainment scaling in patients with lower urinary tract symptoms: development and pilot testing of the Self-Assessment Goal Achievement (SAGA) questionnaire. Int Urogynecol J (2011) 0.84
A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial. J Clin Pharmacol (2007) 0.84
Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder. Am J Manag Care (2005) 0.84
Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase III studies. Urology (2009) 0.84
Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. Neurourol Urodyn (2011) 0.84
Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement? BJU Int (2010) 0.83
Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia. BJU Int (2006) 0.82
Combined effects of behavioral intervention and tolterodine in patients dissatisfied with overactive bladder medication. J Urol (2009) 0.82
Is elective vulvar plastic surgery ever warranted, and what screening should be conducted preoperatively? J Sex Med (2007) 0.82
Contraceptive efficacy of a combined oral contraceptive containing ethinyloestradiol 20 μg/drospirenone 3mg administered in a 24/4 regimen: a pooled analysis of four open-label studies. Eur J Obstet Gynecol Reprod Biol (2011) 0.82
The impact of OAB on physical activity in the United States: results from OAB-POLL. Urology (2013) 0.82
Efficacy and tolerability of fesoterodine in women with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct (2009) 0.81
Patient-optimized doses of fesoterodine improve bladder symptoms in an open-label, flexible-dose study. BJU Int (2010) 0.81
Self-management, amitriptyline, and amitripyline plus triamcinolone in the management of vulvodynia. J Womens Health (Larchmt) (2009) 0.81
A review of quality-of-life questionnaires for urinary incontinence and overactive bladder: which ones to use and why? Curr Urol Rep (2004) 0.81
The psychometric validation of a 1-week recall period for the OAB-q. Int Urogynecol J (2011) 0.80
Vulvovaginal complaints. Clin Obstet Gynecol (2008) 0.80
Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an α-blocker: effect of baseline prostate-specific antigen concentration. BJU Int (2010) 0.80
Onset of efficacy of tolterodine extended release in patients with overactive bladder. Curr Med Res Opin (2007) 0.79
LUTS patient reported outcomes tool: linguistic validation in 10 European languages. Neurourol Urodyn (2012) 0.79
HPV vaccination with Gardasil: a breakthrough in women's health. Expert Opin Biol Ther (2006) 0.79
Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. Br J Clin Pharmacol (2011) 0.79
Vulnerable elderly patients and overactive bladder syndrome. Drugs Aging (2010) 0.79
Vulvar endometriosis presenting with dyspareunia: a case report. J Reprod Med (2012) 0.79
Menopausal women requesting egg/embryo donation: examining health screening guidelines for assisted reproductive technology. Menopause (2016) 0.78
Continued symptom improvement in sexually active women with overactive bladder and urgency urinary incontinence treated with tolterodine ER for 6 months. Int Urogynecol J Pelvic Floor Dysfunct (2009) 0.78
Quality of erections in men treated with flexible-dose sildenafil for erectile dysfunction: multicenter trial with a double-blind, randomized, placebo-controlled phase and an open-label phase. J Sex Med (2007) 0.78
Impact of preventive osteoporosis education on patient behavior: immediate and 3-month follow-up. Menopause (2004) 0.78
Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Curr Med Res Opin (2009) 0.78
Effects of combined behavioral intervention and tolterodine on patient-reported outcomes. Can J Urol (2010) 0.78
Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials. Neurourol Urodyn (2012) 0.78
Moving towards a comprehensive assessment of lower urinary tract symptoms (LUTS). Neurourol Urodyn (2012) 0.78
Presenting symptoms among premenopausal and postmenopausal women with vulvodynia: a case series. Menopause (2015) 0.78